GENELUX Corp (GNLX)
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Genelux Corporation
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 45.25M shares outstanding
USGenelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies.
Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer.
The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Leadership
Eric Groen, J.D.
General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
Jason Litten, M.D.
Chief Medical Officer
John Smither
Director
John Thomas, Ph.D.
Director
Employees
26
Country
US
Sector
Healthcare
Website
genelux.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Yu Yong | Chief Scientific Officer | Sale | 9.7K | $26.7K | Aug 31, 2026 |
 Cappello Joseph | Chief Technical Officer | Sale | 10.3K | $28.1K | Aug 31, 2026 |
 Zindrick Thomas | President and CEO | Sale | 34.5K | $91.9K | Aug 31, 2026 |
| Cappello Joseph | Chief Technical Officer | Sale | 653 | $1.9K | Aug 4, 2026 |
| Yu Yong | Chief Scientific Officer | Sale | 653 | $1.9K | Aug 4, 2026 |
| Zindrick Thomas | President and CEO | Sale | 3.0K | $8.9K | Aug 4, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Armistice Capital, LLC · may incl. warrants· filed Nov 2025 | 4.2M | 9.3% | 13G |
Aladar Szalay · may incl. warrants· filed Feb 2026 | 3.1M | 6.9% | 13G |
Highbridge Capital Management, LLC · filed Oct 2024 | 2.5M | 5.5% | 13G |
WOODWARD DIVERSIFIED CAPITAL, LLC | 2.4M | 5.3% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 1.7M | 3.7% | 13F |
Bleichroeder LP | 1.4M | 3.1% | 13F |
 Zindrick Thomas President and CEO | 1.2M | 2.7% | FORM 4 |
 Thomas John Director | 501.2K | 1.1% | FORM 4 |
BlackRock, Inc. | 439.6K | 1.0% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 439.2K | 1.0% | 13F |
Insiders
- Yu YongChief Scientific Officer
- Cappello JosephChief Technical Officer
- Zindrick ThomasPresident and CEO
- Smither John WDirector
- Mirabelli MaryDirector
- Thomas JohnDirector
- Tyree James LDirector
- Groen EricGeneral Counsel
- Pulisic MatthewChief Financial Officer
- Smalling RalphHead of Regulatory
based on 45.25M shares outstanding
US30d Avg
356.61K
60d Avg
316.29K
90d Avg
334.88K